Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sangamo Therapeutics Inc

1.00
+0.125114.30%
Post-market: 0.9999-0.0001-0.01%19:59 EST
Volume:4.65M
Turnover:4.41M
Market Cap:208.65M
PE:-1.44
High:1.02
Open:0.8562
Low:0.8150
Close:0.8749
Loading ...

Sangamo options imply 10.6% move in share price post-earnings

TIPRANKS
·
01 Nov 2024

Sangamo Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview

Reuters
·
29 Oct 2024

What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You

Simply Wall St.
·
23 Oct 2024

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Sangamo Biosciences (SGMO) and Disc Medicine (IRON)

TIPRANKS
·
23 Oct 2024

Sector Update: Health Care Stocks Softer Tuesday Afternoon

MT Newswires Live
·
23 Oct 2024

Crude Oil Rises Sharply; 3M Posts Upbeat Earnings

Benzinga
·
23 Oct 2024

Sangamo Therapeutics Shares Surge After US FDA Clears Potential Fabry Disease Treatment for Expedited Review

MT Newswires Live
·
22 Oct 2024

Unusually active option classes on open October 22nd

TIPRANKS
·
22 Oct 2024

Sangamo Therapeutics Shares up 27.6% After FDA Feedback for Gene Therapy Study

THOMSON REUTERS
·
22 Oct 2024

BRIEF-Sangamo Therapeutics Announces Alignment With FDA On Accelerated Approval Pathway For St-920 In Fabry Disease With BLA Submission Expected In 2025

Reuters
·
22 Oct 2024

BUZZ-Sangamo Therapeutics rises on FDA feedback for gene therapy study

Reuters
·
22 Oct 2024

Sangamo announces alignment with FDA on ST-920 accelerated approval pathway

TIPRANKS
·
22 Oct 2024

Sangamo Therapeutics: Potential Biologics License Application Submission Expected in H2 of 2025

THOMSON REUTERS
·
22 Oct 2024

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for St-920 in Fabry Disease With Bla Submission Expected in 2025

THOMSON REUTERS
·
22 Oct 2024

Sangamo Therapeutics Inc - FDA Confirms Egfr Slope Data Can Serve as Basis for Approval

THOMSON REUTERS
·
22 Oct 2024

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025

Business Wire
·
22 Oct 2024